News

AKVA Group ASA Sees Growth and Optimism for 2025

AKVA Group ASA Sees Growth and Optimism for 2025

Overview of AKVA Group ASA's Q4 2024 Performance

AKVA Group ASA has reported a quarterly revenue of MNOK 792 in Q4 2024, slightly down by 1% compared to the same period last year. Despite this minor decrease, the company has seen a significant rise in EBITDA, jumping from MNOK 41 in Q4 2023 to MNOK 76 in the latest quarter. The focus on Sea Based technology has proven fruitful, with record-high order intake reported at MNOK 946.

Record High Order Intake

The quarterly order intake for AKVA's Sea Based segment reached an impressive MNOK 946, fueled by the growing demand for deep farming solutions. Overall, the company's total order intake for Q4 2024 surged to BNOK 1.1, which showcases a marked increase from MNOK 718 in Q4 2023. This positive trend highlights the company's strong market position and its commitment to innovation in aquaculture technology.

Contract Awards and Future Projections

A significant RAS contract was secured from Cermaq Chile for a smolt facility, valued at approximately MEUR 30, while another contract with Laxey for re-use technology is expected to bring in additional revenue of around MEUR 20, contingent on financing arrangements. These new contracts are paving the way for AKVA to aim for a revenue target of approximately BNOK 4.0 and an EBIT margin of 6% in 2025.

Quarterly Revenue Breakdown

In examining the revenue distributions, Sea Based Technology (SBT) revenues amounted to MNOK 542 in Q4 2024, showcasing resilience despite a slight fall compared to MNOK 618 from the previous year. EBITDA for this segment remained stable at MNOK 55, with an EBIT margin that remained unchanged. Conversely, the Land Based Technology (LBT) segment demonstrated promising growth, with revenues climbing to MNOK 217 from MNOK 142, reflecting the success of strategic initiatives undertaken by AKVA.

Regional Performance Insights

Geographically, the performance varied with the Nordic region seeing a revenue decline from MNOK 359 to MNOK 344 year-on-year. Similarly, the Americas observed a drop from MNOK 166 to MNOK 146. However, the European market saw more turbulence, with revenue dipping to MNOK 52 compared to the previous MNOK 92 in Q4 2023. It is essential for AKVA to address these regional discrepancies in order to maximize future growth.

Financial Health and Strategy Outlook

AKVA's financial standing remains sound, as indicated by a working capital ratio of 10.1% and a total asset value of MNOK 4,116. The company is compliant with all bank covenants, which ensures financial stability moving forward. The firm is committed to delivering value to its shareholders, with plans to distribute a dividend of NOK 1 per share in the first half of 2025.

Market Outlook and Innovations

The outlook for the aquaculture market is optimistic, with expectations of salmon prices remaining robust due to reduced supply levels. AKVA is also anticipating a recovery in the post-smolt market by 2025. Focused investments in enhancing solutions across Sea Based, Digital, and Land-Based technologies indicate AKVA's commitment to remaining a leader in innovation within the aquaculture sector.

About AKVA Group ASA

With over 1,400 employees and a presence in 12 countries, AKVA Group ASA is a prominent technology and service partner for the global aquaculture industry. The company had a significant turnover of NOK 3.6 billion in 2024, underscoring its status as a leader in the market. AKVA provides a comprehensive range of products, from individual components to complete solutions for both sea and land-based aquaculture, boasting over 40 years of industry experience.

Frequently Asked Questions

What financial results did AKVA Group report for Q4 2024?

In Q4 2024, AKVA Group reported revenues of MNOK 792 and an EBITDA of MNOK 76.

What factors led to AKVA Group's record high order intake?

The record high order intake of MNOK 946 was driven by strong demand in the Nordic market and sales of deep farming solutions.

What are AKVA Group's revenue targets for 2025?

AKVA Group aims for approximately BNOK 4.0 in revenue and an EBIT margin of 6% in 2025.

What new contracts have been secured by AKVA Group?

AKVA has secured contracts with Cermaq Chile and Laxey, totaling significant future revenue potential.

How does AKVA Group plan to reward its shareholders?

The company plans to distribute a dividend of NOK 1 per share in the first half of 2025, reflecting its commitment to shareholder returns.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 5

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 7

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 14

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 5

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading

Top 5 Most Recently Viewed Articles

Red Pine Unveils Exciting Gold Discoveries at Wawa Project

Updated Category News Views 177

Red Pine Exploration's Impressive Drilling Results Red Pine Exploration Inc. (TSXV: RPX, OTCQB: RDEXF) is thrilled to announce outstanding results from its ongoing drilling program at the Wawa Gold Project. This Canadian gold exploration company has executed a comprehensive drilling initiative, totaling 2,793 meters across three drill holes, aiming to unlock the full...

Continue Reading
Silver's Backwardation: What It Means for Investors Today

Updated Category News Views 447

Understanding Silver's Current Market Dynamics Recently, silver's futures market revealed a significant shift, entering a state of backwardation not seen for four decades. This phenomenon indicates that the short-term contract price is considerably higher than longer-term futures, reflecting a dramatic demand for immediate physical silver. The difference of $2.88...

Continue Reading
PGIM High Yield Funds Announce Monthly Distributions

Updated Category News Views 508

PGIM Funds Unveil Distribution Plans for Shareholders NEWARK, N.J.--PGIM High Yield Bond Fund, Inc. (NYSE: ISD), PGIM Global High Yield Fund, Inc. (NYSE: GHY), and PGIM Short Duration High Yield Opportunities Fund (NYSE: SDHY) have announced their monthly distributions for December 2024, January, and February 2025. This initiative signifies their commitment to delivering...

Continue Reading
Investors Urged to Act as Altimmune Faces Legal Challenges

Updated Category News Views 156

Important Legal Investigations Concerning Altimmune, Inc. Faruqi & Faruqi, LLP is currently investigating potential claims on behalf of investors who may have suffered financial losses related to Altimmune, Inc. (NASDAQ: ALT). Investors who acquired securities of Altimmune should pay close attention to this matter, as there are critical developments that could affect...

Continue Reading
Conejo Valley Unified Faces Lawsuits Over Assault Inaction

Updated Category News Views 6

Legal Scrutiny Hits Conejo Valley Unified In what feels like a never-ending cycle of educational mishaps, Conejo Valley Unified School District and its Westlake High School find themselves under the harsh spotlight of the legal system. Two lawsuits filed in Ventura County Superior Court are laying bare some serious accusations against them. Former students, using the...

Continue Reading